Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Li, Hui; Qin, Shukui; Liu, Ying; Chen, Zhendong; Ren, Zhenggang; Xiong, Jianping; Meng, Zhiqiang; Zhang, Xiao; Wang, Linna; Zhang, Xiaojing; Zou, Jianjun

doi:10.2147/dddt.s304857

Cited by 24 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, which have demonstrated encouraging efficacy in the treatment of multiple primary tumors (26)(27)(28)(29)(30). A bulk of studies have shown the favorable efficacy of ICIs on PSC (31)(32)(33) and HCC (34)(35)(36), respectively. Based on the promising outcome of ICIs in HCC, PSC, and MPM patients, this is the first attempt of camrelizumab used for the patient with PSC and HCC, though it has been demonstrated to have anti-tumor activity in HCC patients in the absence of evidence for PSC conventional effective therapies.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

et al. 2022

View full text Add to dashboard Cite

BackgroundWith significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the survival of a broad spectrum of tumors. However, little information is available when it comes to the efficacy, resistance, and underlying mechanisms of ICIs.Case PresentationA 67-year-old woman was diagnosed with pulmonary sarcomatoid carcinoma (PSC) with a history of hepatocellular carcinoma (HCC) and viral hepatitis B. Following the lack of response to systemic chemotherapy, she was treated with camrelizumab, an anti-programmed cell death protein 1 monoclonal antibody, in combination with chemotherapy, and a partial response was obtained both in PSC and HCC. After a course of 9-month treatment, the PSC lesion shrank still, while HCC was evaluated as a progressive disease with an increase in the diameter of liver neoplasm, elevated alpha-fetoprotein, and enlarged abdominal lymph nodes. Then, with the addition of radiotherapy for abdominal metastasis, the lung lesion was continuously shrinking. In the meantime, the liver neoplasm and abdominal lymph nodes showed no significant enlargement.ConclusionCamrelizumab combination therapy could consistently benefit the MPM patients with PSC and HCC, which may be a promising option for patients with MPMs.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A multicenter phase Ib/II study about camrelizumab combined with FOLFOX4 for advanced HCC found that the ORR and DCR were 29.4% and 79.4%, respectively. The median duration of response (DOR), PFS, and OS were 6.9, 7.4, and 11.7 months, respectively (Li et al, 2021). Regarding conversion therapy, there are still some difficult questions to answer, and one is how long the treatment is needed in order to judge the effect.…”

Section: Discussionmentioning

confidence: 99%

Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy

Xie

Liu

Guo

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3 weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3 weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1 year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6 months.

show abstract

“…Similarly, recent preclinical and clinical studies have proved that the combined application of ICIs with transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), and radiotherapy can also promote the efficacy of anti-tumor immunotherapy (40,41). In addition, camrelizumab combined with the chemotherapy regimen FOLFOX4 is being investigated as first-line therapy for advanced HCC in a phase Ib/II clinical trial (42). A summary of the past three years of clinical trials associated with ICIs therapy for HCC is listed in Table 1.…”

Section: Antibody-based Therapy Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu

Liang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

show abstract

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Cited by 24 publications

References 38 publications

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Contact Info

Product

Resources

About